^
    HIF1A overexpression
    HER2 Negative Breast Cancer
    albumin-bound paclitaxel
    Sensitive
    :
    B
    ESMO-BC 2021 - 1wk
    BACH1 overexpression
    HER2 Negative Breast Cancer
    albumin-bound paclitaxel
    Sensitive
    :
    B
    ESMO-BC 2021 - 1wk
    ER mutation
    Estrogen Receptor Positive Breast Cancer
    bevacizumab + paclitaxel
    Sensitive
    :
    C3
    ESMO-BC 2021 - 1wk
    ER positive + PGR positive
    HER2 Negative Breast Cancer
    tamoxifen
    Sensitive
    :
    C3
    ESMO-BC 2021 - 1wk
    PIK3CA mutation
    HER2 Positive Breast Cancer
    trastuzumab + alpelisib + LJM-716
    Sensitive
    :
    C3
    Clin Cancer Res - 1wk
    MYC underexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    HER-2 overexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    FOXA1 overexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    MIA underexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    KRT5 underexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    CDH3 underexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    KRT17 underexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    SFRP1 underexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    CXXC5 overexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    GPR160 overexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    MLPH overexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    GRB7 overexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    KRT14 underexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    No biomarker
    Breast Cancer
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 2wk
    CD276 overexpression
    Triple Negative Breast Cancer
    B7H3-targeted CAR-T immunotherapy
    Sensitive
    :
    D
    ASGCT 2021 - 2wk
    PTEN mutation
    Estrogen Receptor Positive Breast Cancer
    AZD5363
    Sensitive
    :
    C3
    NPJ Breast Cancer - 3wk
    CCNA2 overexpression
    Breast Cancer
    Immunotherapy
    Sensitive
    :
    C3
    Onco Targets Ther - 4wk
    BRCA1 mutation
    Triple Negative Breast Cancer
    olaparib + palbociclib
    Sensitive
    :
    D
    J Exp Clin Cancer Res - 4wk
    HASPIN expression
    Breast Cancer
    CHR-6494
    Sensitive
    :
    D
    PLoS One - 4wk
    BRCA2 mutation
    Triple Negative Breast Cancer
    olaparib + palbociclib
    Sensitive
    :
    D
    J Exp Clin Cancer Res - 4wk
    RB1 negative
    Triple Negative Breast Cancer
    VRN08
    Sensitive
    :
    D
    AACR 2021 - 4wk
    PD-L1 expression
    Triple Negative Breast Cancer
    atezolizumab
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab + tucatinib
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab + pertuzumab
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    margetuximab
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive
    :
    A1
    No biomarker
    Breast Cancer
    docetaxel + doxorubicin hydrochloride + cyclophosphamide intravenous
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    ado-trastuzumab emtansine
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab
    Sensitive
    :
    A1
    No biomarker
    Breast Cancer
    TAC
    Sensitive
    :
    A1
    HR positive
    HER2 Positive Breast Cancer
    neratinib
    Sensitive
    :
    A1
    HR positive
    HER2 Negative Breast Cancer
    palbociclib
    Sensitive
    :
    A1
    HR positive
    HER2 Negative Breast Cancer
    ribociclib
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    pertuzumab/trastuzumab/hyaluronidase-zzxf
    Sensitive
    :
    A1
    PIK3CA mutation + HR positive
    HER2 Negative Breast Cancer
    alpelisib
    Sensitive
    :
    A1
    HR positive
    HER2 Negative Breast Cancer
    abemaciclib
    Sensitive
    :
    A1
    PD-L1 expression
    Triple Negative Breast Cancer
    pembrolizumab
    Sensitive
    :
    A1
    HER-2 amplification
    Hormone Receptor Positive Breast Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 amplification
    HER2 Positive Breast Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 overexpression
    HER2 Positive Breast Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 amplification
    Hormone Receptor Positive Breast Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 amplification
    HER2 Positive Breast Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 overexpression
    HER2 Positive Breast Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive
    :
    A1
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES